Literature DB >> 18397329

Molecular analysis of drug-resistant Mycobacterium tuberculosis isolates collected in central Poland.

E Augustynowicz-Kopeć1, T Jagielski, M Kozińska, A Zabost, M Klatt, Z Zwolska.   

Abstract

In total, 48 Mycobacterium tuberculosis clinical isolates from 48 patients with drug-resistant pulmonary tuberculosis (TB) in central Poland during 2004 were analysed by spoligotyping and IS6110-Mtb1/Mtb2 PCR. Twelve (25%) isolates were clustered by spoligotyping in combination with IS6110-Mtb1/Mtb2 PCR. Patients from whom these isolates were obtained were assumed to have developed TB as a result of recent transmission. Spoligotyping, used alone, overestimated the number of clustered isolates. However, combined use of spoligotyping and IS6110-Mtb1/Mtb2 PCR was an efficient approach for revealing clonal relatedness among M. tuberculosis isolates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397329     DOI: 10.1111/j.1469-0691.2008.02003.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

Review 1.  Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.

Authors:  Tomasz Jagielski; Alina Minias; Jakko van Ingen; Nalin Rastogi; Anna Brzostek; Anna Żaczek; Jarosław Dziadek
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

2.  Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland.

Authors:  Tomasz Jagielski; Ewa Augustynowicz-Kopec; Thierry Zozio; Nalin Rastogi; Zofia Zwolska
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

3.  Genetic diversity of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Poland and assessed by spoligotyping.

Authors:  Ewa Augustynowicz-Kopec; Tomasz Jagielski; Zofia Zwolska
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.